In an editorial piece, Roberta Berard, MD, and Michelle Batthish, MD, highlight the role of a universal access program in improving the health care quality in juvenile idiopathic arthritis.
Researchers sought to determine the mortality rate for pediatric patients with COVID-19 or multisystem inflammatory syndrome in children who experience thrombotic events.
Factors were independently linked to development include atopic dermatitis, family history of psoriasis, skin and fungal infections.
In a systematic review and meta-analysis, study authors evaluated the effectiveness of monoclonal antibodies and anticytokine biologics in the treatment of Kawasaki disease.
The Moderna COVID-19 vaccine may be linked to a higher risk for myocarditis in younger adults than believed.
Researchers assessed whether the COVID-19 pandemic was associated with the occurrence of Kawasaki disease or multi-inflammatory syndrome in children.
Study authors conducted a meta-analysis of randomized controlled trials to study the effectiveness of psychotropic medications in children and adolescents with chronic pain.
Almost half of pediatric opioid prescriptions are considered high-risk by one or more metric.
The Centers for Disease Control and Prevention continues to recommend COVID-19 vaccination for all individuals 12 years of age and older.
Globally, the pooled prevalence estimates for clinically elevated depression and anxiety symptoms almost doubled among children and adolescents during the COVID-19 pandemic.